Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
25405 | 234 | 37.7 | 57% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
332 | 17329 | COMPLEMENT//MANNOSE BINDING LECTIN//PAROXYSMAL NOCTURNAL HEMOGLOBINURIA |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | COMPSTATIN | Author keyword | 15 | 56% | 8% | 18 |
2 | COBRA VENOM FACTOR | Author keyword | 4 | 22% | 7% | 17 |
3 | STELLAR CHANCE S 401 | Address | 3 | 40% | 3% | 6 |
4 | COMPLEMENT DEPLETION | Author keyword | 3 | 42% | 2% | 5 |
5 | C3 INHIBITORS | Author keyword | 2 | 67% | 1% | 2 |
6 | PROTEIN HUMANIZATION | Author keyword | 2 | 67% | 1% | 2 |
7 | COMPLEMENT INHIBITOR | Author keyword | 2 | 19% | 3% | 7 |
8 | COBRA VENOM FACTOR CVF | Author keyword | 1 | 100% | 1% | 2 |
9 | COMPSTATIN ANALOGS | Author keyword | 1 | 100% | 1% | 2 |
10 | HUMANIZED COBRA VENOM FACTOR | Author keyword | 1 | 100% | 1% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | COMPSTATIN | 15 | 56% | 8% | 18 | Search COMPSTATIN | Search COMPSTATIN |
2 | COBRA VENOM FACTOR | 4 | 22% | 7% | 17 | Search COBRA+VENOM+FACTOR | Search COBRA+VENOM+FACTOR |
3 | COMPLEMENT DEPLETION | 3 | 42% | 2% | 5 | Search COMPLEMENT+DEPLETION | Search COMPLEMENT+DEPLETION |
4 | C3 INHIBITORS | 2 | 67% | 1% | 2 | Search C3+INHIBITORS | Search C3+INHIBITORS |
5 | PROTEIN HUMANIZATION | 2 | 67% | 1% | 2 | Search PROTEIN+HUMANIZATION | Search PROTEIN+HUMANIZATION |
6 | COMPLEMENT INHIBITOR | 2 | 19% | 3% | 7 | Search COMPLEMENT+INHIBITOR | Search COMPLEMENT+INHIBITOR |
7 | COBRA VENOM FACTOR CVF | 1 | 100% | 1% | 2 | Search COBRA+VENOM+FACTOR+CVF | Search COBRA+VENOM+FACTOR+CVF |
8 | COMPSTATIN ANALOGS | 1 | 100% | 1% | 2 | Search COMPSTATIN+ANALOGS | Search COMPSTATIN+ANALOGS |
9 | HUMANIZED COBRA VENOM FACTOR | 1 | 100% | 1% | 2 | Search HUMANIZED+COBRA+VENOM+FACTOR | Search HUMANIZED+COBRA+VENOM+FACTOR |
10 | SUBSTITUENT REORDERING | 1 | 100% | 1% | 2 | Search SUBSTITUENT+REORDERING | Search SUBSTITUENT+REORDERING |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | FACTOR HYBRID PROTEINS | 12 | 86% | 3% | 6 |
2 | COMPLEMENT INHIBITOR COMPSTATIN | 11 | 100% | 3% | 6 |
3 | CVF LIKE FUNCTION | 6 | 100% | 2% | 4 |
4 | HUMAN C3 DERIVATIVES | 6 | 100% | 2% | 4 |
5 | INHIBITOR COMPSTATIN | 6 | 100% | 2% | 4 |
6 | DIFFERENT POLYANIONS | 4 | 42% | 3% | 8 |
7 | 2ND C2 | 4 | 38% | 3% | 8 |
8 | 1ST C1 | 3 | 39% | 3% | 7 |
9 | 4TH C4 COMPONENT | 3 | 33% | 3% | 8 |
10 | SYNTHETIC PEPTIDE INHIBITORS | 3 | 50% | 2% | 4 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Humanized cobra venom factor: Structure, activity, and therapeutic efficacy in preclinical disease models | 2014 | 2 | 98 | 36% |
Humanized cobra venom factor: Experimental therapeutics for targeted complement activation and complement depletion | 2007 | 5 | 78 | 42% |
Role of complement and perspectives for intervention in transplantation | 2013 | 7 | 138 | 12% |
Drug design using the example of the complement system inhibitors' development | 2005 | 16 | 35 | 14% |
Taking Complement to the Clinic - has the Time Finally Come? | 2009 | 15 | 58 | 7% |
PHARMACOLOGICAL MANIPULATION OF COMPLEMENT-SYSTEM | 1984 | 49 | 20 | 35% |
INDUCED DEFICIENCIES IN ANIMALS AND MAN | 1986 | 5 | 12 | 42% |
Functional neuroimaging | 1999 | 11 | 21 | 5% |
The complement system: An old story or target of new therapeutic approaches? | 2000 | 6 | 44 | 5% |
Magnetic resonance imaging of Alzheimer's disease | 1996 | 16 | 79 | 4% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | STELLAR CHANCE S 401 | 3 | 40% | 2.6% | 6 |
2 | MED RADIAT BIOL BIOPHYS | 0 | 33% | 0.4% | 1 |
3 | MED INTERDISCIPLINARY IMMUNOL DIS | 0 | 25% | 0.4% | 1 |
4 | NEUROPEPTIDE RECEPTORS | 0 | 25% | 0.4% | 1 |
5 | KLIN POLIKLIN ANAESTHESIOL INTENS MED | 0 | 20% | 0.4% | 1 |
6 | ABT BIOCHEM MOLEKULARBIOL | 0 | 14% | 0.4% | 1 |
7 | PROGRAM DEV IMMUNOL PEDIAT | 0 | 13% | 0.4% | 1 |
8 | PATHOL MEDSTELLAR CHANCE S 401 | 0 | 100% | 0.4% | 1 |
9 | TECH EMORY BIOMED ENGN | 0 | 100% | 0.4% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000206226 | ATYPICAL HEMOLYTIC UREMIC SYNDROME//FACTOR H//C3 GLOMERULOPATHY |
2 | 0.0000176016 | HELIOTROPIUM FILIFOLIUM//FILIFOLINOL//STYPOPODIUM FLABELLIFORME |
3 | 0.0000161974 | C2 DEFICIENCY//COMPLEMENT GENETICS//COMPLEMENT AND INFLAMMATION |
4 | 0.0000148612 | C5A//C5A RECEPTOR//C5AR |
5 | 0.0000119006 | C8 ALPHA//C8 GAMMA//PROPERDIN DEFICIENCY |
6 | 0.0000116289 | NAFAMOSTAT MESILATE//PHARM PHARMACEUT HIGASHINADA KU//MED HOSP PHARM CHUO KU |
7 | 0.0000107244 | MELIACINE//PLANT ANTIVIRAL//TRICHILIA GLABRA |
8 | 0.0000104993 | CD59//CRRY//CD55 |
9 | 0.0000099051 | RGC 32//RESPONSE GENE TO COMPLEMENT 32//BIIG |
10 | 0.0000083928 | ACUTE MYOCARDIAL DISEASE//THANATOCHEMISTRY//COMPLEMENT C9 |